Menopause hormones on TikTok: separating signal from noise

What did @tamsenfadal actually say?

Tamsen Fadal described getting off a call with FDA representatives, organized by women's telehealth company MIDI, where a group of advocates and providers presented women's health concerns directly to agency officials. She said the FDA reps were "really engaged, listening, asking questions and concerned." She framed this as a rare and meaningful moment of institutional attention to women's hormonal health, and closed with a general call to action: don't stay silent. That's essentially the whole claim. No clinical assertions. No dosing advice. No product endorsements beyond naming MIDI.

This is important context: this video is categorized under TRT, but Fadal never mentions testosterone. She's talking about a regulatory advocacy meeting, not a treatment protocol. The emotional core of the clip is about being heard after years of women's health being deprioritized. That framing is worth examining against the actual record.

Does the science back this up?

The broader claim, that women's health has historically been under-studied and under-heard in medical and regulatory settings, is extremely well-supported. This isn't a matter of opinion.

The NIH Revitalization Act of 1993 was passed specifically because women and minorities had been systematically excluded from clinical trials for decades. A 2020 study by Steinberg et al. in the Journal of Women's Health found that even after mandatory inclusion policies, women remain underrepresented in cardiovascular and pain research. On menopause specifically, a 2022 editorial in Menopause journal by Kaunitz and Manson noted that the misinterpretation of the 2002 Women's Health Initiative study created a 20-year gap in HRT prescribing that left millions of women undertreated for menopausal symptoms. The FDA does have a formal Office of Women's Health, established in 1994, and it does conduct stakeholder engagement meetings. So an FDA call of this type is plausible, not remarkable from a procedural standpoint, but clearly meaningful from an advocacy standpoint.

What did they get wrong (or right)?

Fadal gets the historical context right, and she doesn't overclaim. She never says the FDA meeting will produce a specific outcome. She doesn't make clinical promises. She doesn't say hormones are safe, unsafe, or recommend anyone start treatment. That restraint is actually notable for this category of health content.

The one area worth scrutinizing is her implicit framing that social media and companies like MIDI have been the primary engine driving FDA engagement on women's hormonal health. That's an incomplete picture. Academic researchers, ob-gyn professional societies like ACOG and NAMS, and patient advocacy groups have been pushing on these issues for years, largely without TikTok. Telehealth companies have a financial interest in expanded prescribing access, which doesn't make their advocacy wrong, but audiences deserve to know that context. Fadal's presentation, while earnest, positions corporate-backed advocacy as the driving force in a longer and more complicated story.

What should you actually know?

If you're a woman researching hormonal health options because of content like this, here's what the evidence actually supports. Hormone therapy for menopausal symptoms, including estrogen and combined estrogen-progesterone regimens, has a strong evidence base for quality-of-life improvements when initiated in women under 60 or within 10 years of menopause onset. This is the current position of NAMS (2022 position statement) and is broadly accepted among endocrinologists.

Testosterone for women is a separate and more contested area. The Global Consensus Position Statement on testosterone therapy for women (Davis et al., 2019, Journal of Clinical Endocrinology and Metabolism) supports its use specifically for hypoactive sexual desire disorder, but notes the evidence base for other indications is limited. No testosterone product is currently FDA-approved for women in the United States, which means any prescribing is off-label. That's a legitimate clinical practice, but it's not the same as having a fully reviewed approval. If you're being offered testosterone therapy through a telehealth platform, ask about the evidence base for your specific indication and what formulation is being used.

The bottom line on this video

This is an advocacy and awareness post, not a clinical one. Fadal isn't telling you to start hormones or avoid them. She's sharing a moment of institutional engagement that felt meaningful to her. The historical grievance she's pointing at, that women's health concerns have been systematically deprioritized, is factually grounded. The specific framing around who deserves credit for changing that is debatable. There's nothing dangerous here, and nothing that requires a serious correction. It's one of the more responsible uses of a health-adjacent platform this reviewer has come across in this category.